Fractyl Health (GUTS), Monday released 3-month results from the open-label REVEAL-1 Cohort of its REMAIN-1 pivotal trial, showing its Revita procedure may sustain weight loss after stopping GLP-1 therapy.
Of 13 participants who had lost more or less 15% body weight on GLP-1 drugs, 12 maintained or lost additional weight three months after a single Revita treatment half achieved further reduction while typical rebound is 5-6 percent. Median weight change was just plus 0.46 percent, essentially stable from month one.
Revita was well tolerated with no serious adverse events. These findings hint at a potential new approach for durable, drug-free weight maintenance. Fractyl plans to present randomized Midpoint Cohort data in the third quarter, with six-month pivotal results due in H2 2026.
GUTS id currently trading at $1.94, down $0.19 or 9.11 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.